HIV infection may not have a contributory effect on the incidence of invasive cervical cancer (ICC) in women as they age.
Small study also showed that pembrolizumab does not significant impair radiation or chemotherapy dosing.
A literature review noted improvements in quality of life after patients were coached and educated following radiotherapy for HPV-associated oropharyngeal cancers.
Protein produced by chronically infected cells in persons with HPV16 infection serves as a biomarker for risk of cancer of the oropharynx.
Self-persuasion is more effective than external persuasion for motivating low-income parents to vaccinate their children against HPV.
Fewer cervical cell anomalies were present on cervical cancer screens of young women in Canada who received the HPV vaccine through a school-based program.
Although HPV vaccination is expected to decrease the cancer burden from HPV across all racial and ethnic groups, some disparities are expected to persist and widen if their causes are not addressed, including lack of access to screening, timely diagnoses, and treatment.
An analysis has recommended expanding HPV vaccination programs to include males in Canada because it will help protect them against HPV-related cancers.
Oropharyngeal cancer patients with detectable traces of human papillomavirus type 16 (HPV16) in their saliva after cancer treatment are at an increased risk for recurrence.
The presence of certain human papillomavirus (HPV)-16 antibodies in the blood is associated with improved survival rates for patients with HPV-related oropharyngeal carcinoma.
A prospective study found that patients with human papillomavirus-related disease had better treatment response than HPV-negative patients.
A drug typically used to treat infection of the retina in people with AIDS has been shown, for the first time, to sensitize cervical cancer to both chemotherapy and radiotherapy.
An international team of researchers identified two biomarkers that were good at predicting a patient's resistance to radiation therapy for squamous cell cancer of the head and neck.
The quality of cancer stem cells, rather than their quantity, may be the factor that leads to better survival in certain patients with oral cancer.
Researchers from Boston, Massachusetts; Mexico; and Norway have completed a comprehensive genomic analysis of cervical cancer in two patient populations.
The human papillomavirus (HPV) may be to blame for the alarming increase of young adults with oropharyngeal cancer.
A new understanding of the genetic process that can lead to cervical cancer may help improve diagnosis of potentially dangerous lesions for some women.
Antibodies against the human papillomavirus (HPV) may help identify those with a greatly increased risk for HPV-related cancer of the oropharynx.
- Ixazomib, a New PI, Offers Improved Efficacy With Acceptable Toxicity Profile for Relapsed/Refractory Multiple Myeloma
- Acupuncture May Improve Fatigue in Patients with Lung Cancer
- "Light" Cigarettes and Cancer Risk (Fact Sheet)
- A Review of CDK4/6 Toxicities and Interactions Management in Breast Cancer
- Neuropathic Cancer Pain Linked to Reduced Quality of Life
- Dexamethasone-Induced Hiccups in Chemotherapy May be Prevented by Rotating to Methylprednisolone
- New Evidence Shows Metastases May Spread Independently of Lymph Nodes
- Long Term Survivors of Prostate Cancer Express Treatment Decision Regret for Up to 15 Years
- FDA Expands Clearance for Cooling Cap Use With Chemotherapy for Solid Tumors
- Recommendations for Vaccine Administration During Chemotherapy
- Risk for Prostate Cancer Not Associated With Vasectomy, Meta-analysis Affirms
- Disease-Free Survival After Breast Cancer Comparable With Exemestane, Sequential Tamoxifen/Exemestane
- Treating the Other "Patient": Depressive Symptoms Are Predictive of Declining Physical Health in Caregivers
- Oropharyngeal Mucositis Pain Effectively Relieved With Indomethacin Oral Spray
- Opioids Overprescribed in Patients Undergoing Surgery
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|